Clinical Trials Logo

Clinical Trial Summary

Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for refractory/relapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.


Clinical Trial Description

In this study, 20 patients with relapsed refractory B-cell ALL and B-cell NHL were proposed to undergo CD19-BAFF CAR-T cell therapy. Under the premise that its safety has been clarified in previous studies, further observation and evaluation of the effectiveness of CD19-BAFF CAR-T cell therapy for relapsed refractory B-cell ALL and B-cell NHL; At the same time, on the basis of expanding the sample size, more safety data on CD19-BAFF CAR-T cell treatment for relapsed refractory B-cell ALL and B-cell NHL were accumulated, including rare and delayed complications. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06346912
Study type Interventional
Source Zhejiang University
Contact He Huang, MD
Phone 86-13605714822
Email hehuangyu@126.com
Status Recruiting
Phase Early Phase 1
Start date May 30, 2024
Completion date May 30, 2027

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05050461 - Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma N/A
Recruiting NCT06160362 - The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL) N/A
Recruiting NCT04435743 - Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas
Recruiting NCT03720496 - Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy Phase 1
Recruiting NCT05518383 - B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 Phase 4
Recruiting NCT02081937 - CART-19 Immunotherapy in Mantle Cell Lymphoma Phase 1/Phase 2
Recruiting NCT06321289 - Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL Phase 1/Phase 2
Not yet recruiting NCT05909059 - CAR T-cell Therapy in Patients With Renal Dysfunction Phase 2
Recruiting NCT05631912 - TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL Phase 1/Phase 2
Completed NCT04094142 - Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Phase 2
Recruiting NCT05143112 - Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma Phase 1/Phase 2
Recruiting NCT04661020 - CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma Phase 2
Recruiting NCT03497533 - Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 Phase 1/Phase 2
Recruiting NCT04532268 - A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL Early Phase 1
Terminated NCT03488251 - PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Phase 2
Recruiting NCT05741359 - The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma Phase 1
Recruiting NCT04897477 - Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Recruiting NCT06156774 - SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project